Analyst Rating: Will PhaseBio Pharmaceuticals Inc (PHAS) Stock Do Better Than the Market?

Thursday, October 27, 2022 11:03 AM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will PhaseBio Pharmaceuticals Inc (PHAS) Stock Do Better Than the Market?

Wall Street is positive on PhaseBio Pharmaceuticals Inc (PHAS). On average, analysts give PhaseBio Pharmaceuticals Inc a Hold rating. The average price target is $4.5, which means analysts expect the stock to increase by 3650.00% over the next twelve months. That average ranking earns PhaseBio Pharmaceuticals Inc an Analyst Rating of 5, which is better than 5% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating PHAS a Hold today. Find out what this means to you and get the rest of the rankings on PHAS!

See Full PHAS Report

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With PhaseBio Pharmaceuticals Inc Stock Today?

PhaseBio Pharmaceuticals Inc (PHAS) stock is unchanged -0.16% while the S&P 500 has risen 0.04% as of 11:02 AM on Thursday, Oct 27. PHAS is flat $0.00 from the previous closing price of $0.12 on volume of 1,064,993 shares. Over the past year the S&P 500 has fallen -15.81% while PHAS has fallen -96.82%. PHAS lost -$2.13 per share the over the last 12 months. Click Here to get the full Stock Report for PhaseBio Pharmaceuticals Inc stock.